106 results on '"Kristianslund, Eirik Klami"'
Search Results
2. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment
3. Willingness, perceived facilitators and barriers to use remote care among healthcare professionals – a cross-sectional study
4. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
5. ASDAS-CRP and ASDAS-ESR cut-offs for disease activity states in axial spondyloarthritis – Are they interchangeable?
6. Cut-Offs for Disease Activity States in Axial Spondylarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?
7. Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching.
8. Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases.
9. Definition of rheumatoid arthritis flare based on SDAI and CDAI.
10. Definition of rheumatoid arthritis flare based on SDAI and CDAI
11. Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
12. Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching
13. Rheumatology congresses post COVID-19: we cannot regress
14. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries
15. Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching
16. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
17. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis:results from five Nordic biologics registries
18. Data
19. NESTIMATOR
20. After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries
21. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study
22. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
23. European bio-naïve spondyloarthritis patients initiating TNF inhibitor:time trends in baseline characteristics, treatment retention and response
24. Association between Lower Extremity Muscle Strength and Noncontact ACL Injuries
25. After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
26. European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response
27. Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers.
28. European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response
29. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment - Results from 12 countries in EuroSpA
30. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
31. The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission status
32. Impact of discordance between patient’s and evaluator’s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis
33. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment:routine care data from 12 registries in the EuroSpA collaboration
34. The Effect of Thigh Marker Placement on Knee Valgus Angles in Vertical Drop Jumps and Sidestep Cutting.
35. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpA
36. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
37. No Association Between Risk of Anterior Cruciate Ligament Rupture and Selected Candidate Collagen Gene Variants in Female Elite Athletes From High-Risk Team Sports
38. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
39. Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls
40. Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration
41. No Association Between Risk of Anterior Cruciate Ligament Rupture and Selected Candidate Collagen Gene Variants in Female Elite Athletes From High-Risk Team Sports.
42. Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan- European collaboration of registries.
43. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study
44. Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example.
45. Opportunities and challenges for realworld studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example.
46. The Effect of Thigh Marker Placement on Knee Valgus Angles in Vertical Drop Jumps and Sidestep Cutting
47. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
48. Håndballfinter og korsbåndsskader
49. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA
50. Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic Registries.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.